FDA Approves OXCARBAZEPINE — Chartwell RX, LLC

# FDA Approves Generic Oxcarbazepine for Chartwell RX Chartwell RX, LLC received FDA approval for its generic oxcarbazepine oral formulation, expanding the competitive generic anticonvulsant market and providing patients with a lower-cost treatment alternative for seizure disorders and nerve pain. The approval is expected to increase pricing pressure on branded oxcarbazepine products while strengthening Chartwell RX's portfolio in the high-volume generic neurological drug segment.